HHS Overhauls Bioweapon Countermeasure And Pandemic Defence Capabilities

BMI View: Despite government incentives for the US bioweapon countermeasure market segment, biotechnology companies are likely to remain cautious, given the small profit margins and the unpredictability of demand for products addressing biological threats. Nevertheless, influenza vaccine manufacturers will benefit significantly from anti-pandemic investments, mainly through technology upgrades and increases in manufacturing flexibility used to address seasonal

To read the full article, please choose one of the following options: